Drug profile

The FDA adverse-event record for S Adenosylmethionine And Silybin

11 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference S Adenosylmethionine And Silybin. See the species affected, top reactions, and outcomes below.

11
adverse-event reports
36.4%
death-coded share
Dog
most-reported species
3
Limb weakness - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
4
Deaths Reported
36.4%
Death Rate

Active Ingredients

S Adenosylmethionine And Silybin

Administration Routes

UnknownOral

Species Affected

Dog 11

Most Affected Breeds

Retriever - Labrador 2
Deutsche Dogge, Great Dane 2
Crossbred Canine/dog 1
Pinscher - Miniature 1
Pointing Dog - German Short-haired 1
Terrier (unspecified) 1
Hound (unspecified) 1
Spaniel (unspecified) 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Limb weakness 3
Abnormal radiograph finding 3
Death by euthanasia 3
Lethargy (see also Central nervous system depression in Neurological) 3
Decreased appetite 3
Elevated serum alkaline phosphatase (ALP) 2
Proprioception deficit 2
Weakness 2
Panting 2
Elevated liver enzymes NOS 2
Shaking 2
Seizure NOS 2

Outcome Breakdown

Ongoing
7 (63.6%)
Euthanized
3 (27.3%)
Died
1 (9.1%)

S Adenosylmethionine And Silybin Adverse Event Insights

11 reports name S Adenosylmethionine And Silybin; 4 recorded a death outcome (36.4% of reported events, not a population-level mortality rate). Active ingredient: S Adenosylmethionine And Silybin. Administration routes: Unknown, Oral.

By species: Dog (11 reports). By breed: Retriever - Labrador (2), Deutsche Dogge, Great Dane (2), Crossbred Canine/dog (1).

Leading clinical signs: Limb weakness (3), Abnormal radiograph finding (3), Death by euthanasia (3), Lethargy (see also Central nervous system depression in Neurological) (3). Outcome, 11 coded reports: Ongoing leads at 63.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.